STIFEL 2026 HEALTHCARE CONFERENCE - XENON PHARMACEUTICALS INC

Financial Performance:

• Ended Q3 with $1.2 billion in cash, providing a runway extending through 2029.
• Anticipates 2028 as the commercial launch window for Axitacalner, meaning 2026-2027 will be high-burn years to fund commercial infrastructure build-out and clinical pipelines prior to revenue generation.
• No immediate revenue is expected; financial focus remains on capitalizing R&D and commercial preparation for the 2028 launch.

Guidance and Future Outlook:

• Axitacalner (Zutacalner) NDA filing submitted in September; expected FDA review is standard, with commercial launch targeted for early 2028 (January).
• Psychiatry (MDD) unblinding for the EXNOVA-2 Phase 3 study scheduled for December to inform future regulatory strategy with the FDA.
• Pain portfolio assets (XCN1701 and XCNE1120) will enter Phase 2 proof-of-concept studies for acute pain in 2026.
• Future revenue growth is projected to be gradual rather than exponential ("hockey stick"), with initial sales expected to be a fraction of peak, mirroring historical trends for anti-seizure medications.

Business Segments and Product Lines:

• Epilepsy (Axitacalner): Two completed large randomized placebo-controlled studies show excellent efficacy (best placebo-adjusted efficacy in focal seizures) and novel mechanism (potassium channel modulation); commercialization strategy focuses on add-on therapy rather than first-line monotherapy.
• Psychiatry: Voluntary pause on Phase 3 enrollment (EXNOVA-2) lifted; study design adjusted to a 360-subject cohort with 90% power to detect a 2.5-point separation on HEMD17; safety profile remains under review pending December data.
• Pain Portfolio: Two distinct assets entering Phase 2: XCN1701 (Nav1.7 inhibitor) and XCNE1120 (KV7 modulator); Phase 1 data met target product profiles with no observed autonomic side effects for XCN1701.
• Pipeline Expansion: X-FIRST Phase 3b study in epilepsy initiated; NAV1.7 second-generation molecule in Phase 1; NAV1.1 small molecule for Dravet syndrome in IND-enabling studies.

Market and Competitive Landscape:

• Enters a market with significant generic competition but limited recent innovation; last branded launch for focal seizures was Sonobamate (2019).
• Pricing strategy aims to exceed Sonobamate ($15,400 annually) and match/undercut prior market leader Prialt (now off-patent, ~$18,000), leveraging superior clinical data and ease of use.
• Targeting "first add-on" positioning where patients have failed generic SV2A or sodium channel blockers, rather than competing directly as monotherapy against generics.
• Differentiation against general neurologists: Simplified dosing (4 on-label doses, no titration required, no need to taper other ASMs) addresses barriers preventing broader adoption of competitors like Sonobamate.

Risks and Challenges:

• Psychiatric Safety: Potential for rare adverse events (e.g., psychosis) similar to other potent CNS drugs like Levetiracetam (Keppra); historical data shows these resolve without long-term sequelae, but FDA interaction required to confirm path forward for MDD indication.
• Commercial Adoption: Conservative prescribing habits ("low and slow") by physicians may delay revenue ramp-up; overcoming general neurologist hesitation regarding CNS adverse events and complex titration regimens of competitors.
• Cash Burn: High burn rate expected in 2026-2027 to build sales teams and commercial infrastructure before the 2028 launch.

Management Commentary and Tone:

• Tone is confident and forward-looking, emphasizing the novelty of the potassium channel modulation mechanism and the strength of the clinical package.
• Management expressed comfort with the safety profile of Axitacalner, noting it is well-understood within the epilepsy community and consistent with established ASMs.
• Clear strategic pivot: Prioritizing the epilepsy launch while using MDD data to potentially enhance the epilepsy value proposition or explore the MDD indication if data supports it.

Analyst Questions and Answers:

• Safety/Psychosis: Clarified that psychosis is a rare, reversible event (<1% rate, similar to Keppra) seen at higher doses (20-25mg); low doses (10-15mg) are placebo-like.
• MDD Path Forward: Confirming that post-unblinding, a meeting with the FDA is required to determine if development continues for the MDD indication or focuses solely on epilepsy; data will be published regardless.
• Pain Mechanism: Confirmed Nav1.7 target is "exquisite" based on genetic loss-of-function phenotypes; Phase 2 designs will utilize acute pain models (e.g., bunionectomy) to establish proof-of-concept before moving to chronic indications.
• Pricing Power: Management asserts a "position of strength" due to lack of recent innovation, superior efficacy data, and a simplified dosing regimen compared to competitors.

Other Key Points:

• The company is preparing a full commercial package, including market access negotiations with payers to optimize pricing and access.
• Executive leadership team (CCO) is largely in place; sales force recruitment will accelerate as launch approaches.
• Emphasis on "ease of use" as a key differentiator for general neurologists, removing the complexity of titration and interaction management required by current branded options.